back to US directory
us clinical guidance

Trigeminal neuralgia recognition and specialist treatment

US phenotype recognition, structural-cause evaluation, medication safety and neurosurgical referral for trigeminal neuralgia.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with brief recurrent unilateral electric-shock facial pain in a trigeminal distribution. The AAN/EFNS guideline is from 2008 but was reaffirmed in 2024; its age and evidence limitations are explicit. Persistent aching facial pain, dental disease, postherpetic neuralgia, trigeminal autonomic cephalalgia and secondary neuralgia need diagnostic separation.
sources for this section:AAN/EFNS TN 2008

The Bottom Line

  • Recognize stereotyped seconds-to-minutes paroxysms triggered by light touch, chewing, talking or oral care, with pain confined to one or more trigeminal divisions and usually no deficit between attacks.
  • Perform a complete cranial-nerve and sensory examination and obtain brain MRI with an appropriate cranial-nerve protocol when feasible to evaluate tumor, multiple sclerosis or another structural cause.
  • Carbamazepine and oxcarbazepine are established first-line options in the reaffirmed guideline; choose and monitor according to current FDA labeling, ancestry-related pharmacogenetic risk, sodium, blood counts and liver function.
  • Refer medication-refractory, intolerant or diagnostically uncertain disease to experienced neurology and neurosurgery for individualized procedural discussion rather than escalating indefinitely without review.
sources for this section:AAN/EFNS TN 2008

Practical clinical workflow

1
Map the pain precisely, document attack duration and triggers, ask about continuous pain, autonomic symptoms, rash, dental procedures, numbness, hearing change and multiple-sclerosis features.
2
Examine oral and dental structures, cornea, facial sensation and motor function and other cranial nerves; investigate atypical age, bilaterality or sensory loss promptly.
3
Before treatment, reconcile interactions and baseline laboratory risks, start cautiously, educate about rash and toxicity and measure attack frequency and functional response.
4
If control is inadequate, verify adherence and diagnosis, optimize or change medication with specialist input and review procedure benefits, recurrence, sensory loss and anesthesia-dolorosa risk.
sources for this section:AAN/EFNS TN 2008

Safety boundaries and escalation

  • New facial numbness, corneal reflex loss, hearing loss, other cranial neuropathy, bilateral symptoms or progressive deficit raises concern for a secondary lesion and needs expedited imaging.
  • A severe mucocutaneous rash, fever, blood dyscrasia symptoms, hepatic injury, profound hyponatremia or suicidality during antiseizure therapy requires urgent evaluation and medication action.
  • Do not diagnose trigeminal neuralgia solely from facial pain without excluding dental infection, giant-cell arteritis, glaucoma, sinus disease, herpes zoster and primary headache syndromes.
  • Inability to eat or drink, uncontrolled continuous pain or rapidly escalating attacks can cause dehydration and crisis-level distress and may require urgent specialist or hospital care.
sources for this section:AAN/EFNS TN 2008

Localization

The AAN/EFNS source is reaffirmed but materially older, so every drug and procedure statement needs current US clinical review and FDA-label checking. Insurance authorization and neurosurgical availability vary.
sources for this section:AAN/EFNS TN 2008

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of Neurology and European Federation of Neurological SocietiesThe Diagnostic Evaluation and Treatment of Trigeminal Neuralgia2008 practice guideline; reaffirmed 2024-04-15 路 published 2008-10-01 路 updated 2024-04-15 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.